On Jan. 15, Eli Lilly & Company (Lilly) announced that starting Feb. 1 it will require all 340B covered entities to submit claims-level data (CLD) for all dispenses of Lilly drugs, regardless of ...
On June 25, 2026, Senate HELP Committee Chairman Bill Cassidy (R-LA) released a sweeping legislative discussion draft titled the 340B Drug Pricing Integrity and Affordability for Patients Act. This ...
For three decades, hospitals and healthcare systems in the 340B Drug Pricing Program have operated with a common purpose: serve vulnerable communities and stretch scarce federal resources while ...
As U.S. healthcare costs, overall, increase each year, Rachelle Schultz, president and CEO of Winona Health, knows that pharmaceutical spending is her health system’s fastest-growing expense — as much ...
The 340B Drug Pricing Program is a federal program in which participating hospitals and clinics are able to purchase qualifying drugs from pharmaceutical manufacturers at Medicaid-like pricing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results